DVHGF (Devonian Health Group) Common Stock: $22.99 Mil (As of Apr. 2026)


DVHGF Devonian Health Group Inc DVHGF
49 GF Score
Price $7.00
GF Value $1.98
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Devonian Health Group Common Stock?

Devonian Health Group DVHGF 49 Common Stock is $22.99 Mil as of Apr. 2026. GuruFocus rates DVHGF with a GF Score™ of 49/100 and a GF Value™ of $1.98 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Devonian Health Group's quarterly common stock increased from Oct. 2025 ($22.45 Mil) to Jan. 2026 ($22.80 Mil) and increased from Jan. 2026 ($22.80 Mil) to Apr. 2026 ($22.99 Mil).

Devonian Health Group's annual common stock declined from Jul. 2023 ($22.21 Mil) to Jul. 2024 ($21.76 Mil) but then increased from Jul. 2024 ($21.76 Mil) to Jul. 2025 ($21.79 Mil).

Devonian Health Group Common Stock Historical Data

* Premium members only.

The historical data trend for Devonian Health Group's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Devonian Health Group Common Stock Chart

Devonian Health Group Annual Data
Trend Jun16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.13 21.31 22.21 21.76 21.79

Devonian Health Group Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.34 21.79 22.45 22.80 22.99
DVHGF
49GF Score
Devonian Health Group Inc DVHGF
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Devonian Health Group Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $22.99 Mil mean?
Devonian Health Group (DVHGF) has a Common Stock of $22.99 Mil as of Apr. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Devonian Health Group and its competitors.
Is Devonian Health Group's Common Stock too high?
Devonian Health Group's current Common Stock is $22.99 Mil. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Common Stock compare to VRTX and REGN?
Devonian Health Group's Common Stock of $22.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current Common Stock is $22.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.98, compared to a current price of $7.00 — trading 253.5% above its estimated fair value. The current Common Stock is $22.99 Mil. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Common Stock is $22.99 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Devonian Health Group (DVHGF) Overvalued in 2026?

Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued. The current stock price of $7.00 is trading 253.5% above its estimated GF Value™ of $1.98. GuruFocus considers Devonian Health Group to be Significantly Overvalued.

Key valuation signals for DVHGF:

  • Common Stock: $22.99 Mil
  • GF Value™: $1.98 vs. price of $7.00 (253.5% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Devonian Health Group Business Description

Other Exchanges GSD:Canada
Address 360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score

Get the complete analysis for DVHGF

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.00
Price
$1.98
GF Value